Sorafenib and two other multiple kinase inhibitors (BPR1J419S1 and BPR1J420S1) have been proved to prevent HCC in HBx, src, and p53−/+ transgenic fish [58]. The gene discussed is TP53; the disease is hepatocellular carcinoma.